(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 14.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Mannkind's revenue in 2025 is $297,595,000.On average, 3 Wall Street analysts forecast MNKD's revenue for 2025 to be $98,335,346,735, with the lowest MNKD revenue forecast at $94,918,229,680, and the highest MNKD revenue forecast at $100,610,891,998. On average, 3 Wall Street analysts forecast MNKD's revenue for 2026 to be $113,146,906,411, with the lowest MNKD revenue forecast at $101,148,853,146, and the highest MNKD revenue forecast at $123,035,057,818.
In 2027, MNKD is forecast to generate $135,978,038,321 in revenue, with the lowest revenue forecast at $126,803,825,183 and the highest revenue forecast at $145,152,251,458.